BioSpace News Archive

Portage Biotech is pleased to announce that it has completed the distribution of shares of Biohaven Pharma to all eligible Portage shareholders.

The Annual Report on Form 10-K contains information pertaining to the Company’s interim quarterly, year-to-date and annual results for 2016 and 2015.

Catalyst OrthoScience has been granted four new patents by the United States Patent and Trademark Office for technologies incorporated in the CSR Total Shoulder Replacement System.

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Japanese Ministry of Health, Labour and Welfare has approved LYNPARZA® (olaparib) tablets (300mg twice daily) for use as a maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer, regardless of their BRCA mutation status, who responded to their last platinum-based chemotherapy.

Quest Diagnostics announced that it will report fourth quarter and full year 2017 results on Thursday, February 1, 2018, before the market opens.

The findings being presented come from patients that had received placebo in a previous Phase 2 double-blind, placebo-controlled study.

In both publications, well-characterized kinase inhibitors were converted to degraders by conjugation with a thalidomide derivative that binds the Cereblon E3 ubiquitin ligase.

The results were published in the January/February issue of the JWOCN, the peer-reviewed publication of the Wound, Ostomy and Continence Nurses Society.

Magno-Humphries Laboratories, Inc., is voluntarily recalling one lot of Basic Drugs Brand of Senna Laxative tablets, 8.6mg Sennosides to the consumer level due to a customer complaint that their bottle labeled as Senna Laxative actually contained Basic Drugs Brand of Naproxen Sodium 220mg.

An analysis of patients with newly diagnosed, locally advanced pancreatic cancer treated with up to 6 cycles of ABRAXANE + gemcitabine as an investigational induction therapy (n=106) found that patients had a median time to treatment failure (TTF) of 8.8 months (90% CI: 6.67-9.82), which exceeded the protocol-specified target of 6.6 months (primary endpoint).